Invizius Receives MHRA Approval to Commence First-in-Human Clinical Study of H-Guard® Priming Solution

H-Guard® will be evaluated for its safety and efficacy to address serious complement driven complications of haemodialysis GLASGOW, Scotland, Aug. 1, 2023 /PRNewswire/ — Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of…